(PCVX) Vaxcyte - Overview
Stock: Pneumococcal, Streptococcus, Periodontitis, Shigellosis
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 46.7% |
| Relative Tail Risk | -7.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.25 |
| Alpha | -50.27 |
| Character TTM | |
|---|---|
| Beta | 0.781 |
| Beta Downside | 0.726 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.22% |
| CAGR/Max DD | 0.11 |
Description: PCVX Vaxcyte January 08, 2026
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology firm focused on next-generation conjugate and protein vaccines targeting bacterial infections. Founded in 2013 and headquartered in San Carlos, California, the company rebranded from SutroVax in May 2020.
The flagship program is VAX-24, a 24-valent carrier-sparing pneumococcal conjugate vaccine (PCV) intended for infants to prevent invasive pneumococcal disease (IPD). A second PCV, VAX-31, expands coverage to 31 serotypes and is being positioned for both adult and pediatric markets.
Beyond pneumococcal vaccines, Vaxcyte’s pipeline includes VAX-A1 (a Group A Streptococcus conjugate vaccine), VAX-PG (a protein vaccine against the keystone pathogen of periodontitis), and VAX-GI (a preclinical candidate for Shigella-induced dysentery). The company leverages a carrier-sparing platform that could reduce manufacturing complexity and cost.
Key financial and market metrics (Q3 2024): market capitalization ≈ $650 million, cash on hand ≈ $120 million, quarterly cash burn ~ $30 million, and a share price around $6.5. Vaxcyte has a development partnership with Sanofi for VAX-24, which could accelerate regulatory timelines and provide commercial scale. The global PCV market is projected to grow at a ~7 % CAGR through 2030, driven by expanding pediatric immunization programs and increasing demand for broader serotype coverage.
For a deeper, data-driven look at how Vaxcyte’s valuation compares to peers, you might find the analytics on ValueRay worth a quick glance.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -542.1m > Net Income -657.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.2m) vs 12m ago 10.11% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.41%; Δ -0.41% > 0%) |
| Interest Coverage Ratio: -15.58 > 6 (EBITDA TTM -599.8m / Interest Expense TTM 39.6m) |
Altman Z'' -7.14
| A: 0.49 (Total Current Assets 1.77b - Total Current Liabilities 200.0m) / Total Assets 3.17b |
| B: -0.60 (Retained Earnings -1.91b / Total Assets 3.17b) |
| C: -0.18 (EBIT TTM -617.6m / Avg Total Assets 3.37b) |
| D: -6.84 (Book Value of Equity -1.91b / Total Liabilities 278.7m) |
| Altman-Z'' Score: -7.14 = D |
What is the price of PCVX shares?
Over the past week, the price has changed by +4.82%, over one month by +25.20%, over three months by +34.62% and over the past year by -36.92%.
Is PCVX a buy, sell or hold?
- StrongBuy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PCVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.1 | 81.9% |
| Analysts Target Price | 102.1 | 81.9% |
| ValueRay Target Price | 58.3 | 3.8% |
PCVX Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -617.6m USD
EBITDA TTM = -599.8m USD
Long Term Debt = 84.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 84.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -196.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.39b USD (7.01b + Debt 84.4m - CCE 1.71b)
Interest Coverage Ratio = -15.58 (Ebit TTM -617.6m / Interest Expense TTM 39.6m)
EV/FCF = -9.11x (Enterprise Value 5.39b / FCF TTM -591.5m)
FCF Yield = -10.98% (FCF TTM -591.5m / Enterprise Value 5.39b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.99m) / Revenue TTM)
Tobins Q-Ratio = 1.70 (Enterprise Value 5.39b / Total Assets 3.17b)
Interest Expense / Debt = 12.71% (Interest Expense 10.7m / Debt 84.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -487.9m (EBIT -617.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.83 (Total Current Assets 1.77b / Total Current Liabilities 200.0m)
Debt / Equity = 0.03 (Debt 84.4m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -196.6m / EBITDA -599.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -196.6m / FCF TTM -591.5m)
Total Stockholder Equity = 3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.53% (Net Income -657.2m / Total Assets 3.17b)
RoE = -21.08% (Net Income TTM -657.2m / Total Stockholder Equity 3.12b)
RoCE = -19.29% (EBIT -617.6m / Capital Employed (Equity 3.12b + L.T.Debt 84.4m))
RoIC = -15.65% (negative operating profit) (NOPAT -487.9m / Invested Capital 3.12b)
WACC = 8.80% (E(7.01b)/V(7.10b) * Re(8.79%) + D(84.4m)/V(7.10b) * Rd(12.71%) * (1-Tc(0.21)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.20%
Fair Price DCF = unknown (Cash Flow -591.5m)
EPS Correlation: -2.86 | EPS CAGR: 12.43% | SUE: 4.0 | # QB: 1
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.53 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-6.22 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=-19.8% | Growth Revenue=+0.0%